This site is intended for heath plan professionals in Canada.
This site is intended for health plan professionals in Canada.
U.S. professionals should visit ManagedCareCGM.com
This site is intended for health plan professionals in Canada.
U.S. professionals should visit ManagedCareCGM.com
CGM Associated with Reduced Cost and Health Care Resource Utilization in Intensive Insulin-Treated T2D – Advances in Therapy – April 15, 2024
CGM Improves Glycemic Control and Reduces CVD Risk in Non-Insulin-Treated T2D – Diabetes Obesity and Metabolism – April 28, 2024
Study Finds Poor Attainment of Glycemic Targets Among Canadian Adults with Diabetes– Canadian Journal of Diabetes – September 11, 2023
Evidence-Based Rationale for Expanding Access to CGM in Individuals with Type 2 Diabetes Treated with Nonintensive Therapies – Diabetes Technology & Therapeutics – August 2023
New Supplement Highlights the Latest CGM Evidence and Insights – Diabetes Technology and Therapeutics – June 2023
LOIS-P Looks at Hypoglycemia Incidence with Sensor-Augmented Pump in Pregnancy – Diabetes Technology and Therapeutics
LOIS-P Study Examines Insulin Use and Glycemic Control in Pregnancy with CGM – Diabetes Technology and Therapeutics – November, 2021
Blood Glucose Monitoring in Adults and Children with Diabetes: Update 2021 – Canadian Journal of Diabetes – 2021
American Association of Clinical Endocrinology [AACE] Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus – AACE Endocrine Practice – June 2021
Diabetes Technology Standards of Medical Care in Diabetes 2021 – American Diabetes Association – Diabetes Care – 2021
This website is supported by an educational grant from Dexcom, Inc.
